Jenna Bailey, OD
Optometrist · Toledo, OHNPI 1659891943
Payments from drug & device makers
Across 145 payments — averaging $48.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$2K
- AbbVie$809
- Bausch & Lomb Americas Inc.$749
- Alcon$612
- Johnson & Johnson Vision Care, Inc.$484
- Sun Pharmaceutical Industries Inc.$451
- plus $2K from 13 others
What the payments were for
- Travel & lodging$72910%
- Food & beverage$6,26190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 21 | $2,077 |
| AbbVie(2 entities) | 21 | $809 |
| Bausch & Lomb Americas Inc. | 13 | $749 |
| Alcon | 16 | $612 |
| Johnson & Johnson Vision Care, Inc. | 13 | $484 |
| Sun Pharmaceutical Industries Inc. | 9 | $451 |
| Tarsus Pharmaceuticals, Inc. | 10 | $420 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $338 |
| Shire North American Group Inc | 6 | $258 |
| Dompe US, Inc. | 5 | $196 |
| Kala Pharmaceuticals, Inc. | 4 | $146 |
| Oyster Point Pharma, Inc. | 2 | $112 |
| Amgen | 2 | $102 |
| Harrow Eye, LLC | 3 | $70 |
| Coopervision Inc. | 4 | $69 |
| Novartis | 3 | $56 |
| Alimera Sciences, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $12 |
| Visioneering Technologies, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,990 in reported general payments places this provider in the 90th percentile of 1,995 optometrist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 57 | $67,834 |
| RestasisCyclosporine | 58 | $67,818 |
| Restasis MultidoseCyclosporine | 44 | $29,366 |
| MieboPerfluorohexyloctane/Pf | 20 | $22,430 |
| Cyclosporine | 46 | $20,622 |
| CequaCyclosporine | 25 | $17,647 |
| LumiganBimatoprost | 24 | $12,608 |
| VyzultaLatanoprostene Bunod | 22 | $12,459 |
| TyrvayaVarenicline Tartrate | 16 | $10,829 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $6,757 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $5,883 |
| Brimonidine Tartrate | 63 | $5,773 |
| Latanoprost | 346 | $4,459 |
| Bimatoprost | 16 | $1,814 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 59 | $1,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose, Lumigan | $809 | $109,791126 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $749 | $102,72399 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $451 | $17,64725 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $112 | $10,82916 claims |
| AlconSimbrinza | $612 | $5,88321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,995 optometrist providers in Ohio.
Other optometrist in Toledo
- Katherine BickleGranville$3M
- Jennifer FogtColumbus$1.9M
- Jason MillerPowell$1.4M
- Mile BrujicBowling Green$1.3M
- William LayWesterville$891K
- Gregory DenaeyerColumbus$846K
- Thomas ChesterCleveland$786K
- Loretta Szczotka-FlynnCleveland$388K
- Cory LappinMontgomery$367K
- Dustin GardnerMarysville$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.